L1 Technology Package for Diagnosis & Therapy of Ovarian and Endometrial Cancer
L1 is overexpressed in highly malignant carcinomas and human ovarian tumors. The antibody 9.3 has improved anti-tumor capacities by inhibit tumor growth and invasion of tumor cells. Antibody can be also used to determine the L1 level in a patient.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Retinoblastoma: Eye-Catching Investigation into Retinal Tumor Cells
A research team from the Medical Faculty of the University of Duisburg-Essen and the University Hospital Essen has developed a new cell culture model that can be used to better…
A Job Well Done: How Hiroshima’s Groundwater Strategy Helped Manage Floods
Groundwater and multilevel cooperation in recovery efforts mitigated water crisis after flooding. Converting Disasters into Opportunities Society is often vulnerable to disasters, but how humans manage during and after can…
Shaping the Future: DNA Nanorobots That Can Modify Synthetic Cells
Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of “DNA origami”. The system they developed may facilitate the…